Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Target Price from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $22.25.

Several research firms have recently weighed in on ACRS. BTIG Research reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Thursday, January 11th. HC Wainwright lowered Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Friday, January 12th.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently bought and sold shares of the business. BML Capital Management LLC bought a new stake in Aclaris Therapeutics during the 4th quarter worth approximately $686,000. Vanguard Group Inc. lifted its holdings in Aclaris Therapeutics by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock worth $23,037,000 after buying an additional 33,482 shares in the last quarter. Trexquant Investment LP acquired a new position in Aclaris Therapeutics during the 3rd quarter worth $876,000. SG Americas Securities LLC lifted its holdings in Aclaris Therapeutics by 20.1% during the 3rd quarter. SG Americas Securities LLC now owns 151,704 shares of the biotechnology company’s stock worth $1,039,000 after buying an additional 25,357 shares in the last quarter. Finally, Blackstone Inc. lifted its holdings in Aclaris Therapeutics by 9,578.7% during the 3rd quarter. Blackstone Inc. now owns 1,261,425 shares of the biotechnology company’s stock worth $8,641,000 after buying an additional 1,248,392 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $1.36 on Friday. The company’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.59. The firm has a market capitalization of $96.91 million, a PE ratio of -1.07 and a beta of 0.23. Aclaris Therapeutics has a 52-week low of $0.59 and a 52-week high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. The business had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. Analysts predict that Aclaris Therapeutics will post -0.98 earnings per share for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.